Clinical Trial Update: Single Ascending Dose Safety Study of Oxfendazole [Phase 1]

View source ↗

Summary

The clinical trial update indicates that a Phase 1 single ascending dose safety study of oxfendazole for Taenia solium infection has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cysticercosis
• Taeniasis

Drugs mentioned

• Oxfendazole (oxfendazole)

Snippet

Sponsor: Johns Hopkins Bloomberg School of Public Health | Conditions: Tenia Solium Infection | Phase 1 | Status: WITHDRAWN